Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions

NCT ID: NCT01209156

Last Updated: 2013-11-11

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 11 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-03-31
• Study Completion Date: 2013-06-30

Brief Summary

The underlying goal of this study is to assess PBR-111 positron emission tomography (PET) imaging as a tool to detect microglial activation in the brain of Alzheimer disease (AD) research participants and age- and gender-matched healthy volunteers.

Detailed Description

This is a phase 1, open-label, single-center, non-randomized single dose study to assess the kinetics, clearance and cerebral distribution of PBR-111 positron emission tomography (PET) imaging in detecting microglial activation in the brain in patients with probable Alzheimer disease (AD) compared to healthy volunteers (HVs). All aspects related to image acquisition, processing and visual as well as quantitative evaluation will be developed, optimized and validated (where required).

Each subject will be required to visit the study center during the screening phase and on the PBR-111 PET imaging day (baseline). A telephone follow-up visit will be performed 7 days (+/- 3 days) after PBR-111 PET administration.

At the screening visit, each subject (or caregiver in the case of AD subjects) will be asked to provide written informed consent or assent. During the screening phase (maximum duration - 60 days) subject medical, neurological and surgical history, clinical assessments and a neuro-psychiatric evaluation will be performed on all eligible subjects. Subjects will be allowed to leave the center after all evaluations have been completed. During this period an MRI of the brain will be performed. During the PBR-111 PET imaging day, all subjects will receive a single IV injection of PBR-111 and scanning will be performed over a 3.5 hour period. Each subject will have a telephone follow-up 7 days (+/- 3 days) thereafter to assess for adverse events.

Conditions

Alzheimer Disease

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Assess [18F] PBR111 and PET imaging

Evaluation of PET imaging with \[18F\]PBR111 in HV and AD subjects (Proof of Mechanism)

Group Type: EXPERIMENTAL

[18F] PBR111

Intervention Type: DRUG

Subjects will be injected with 5mCi (not to exceed a maximum of 5.5 mCi) of \[18F\]PBR111, followed by PET imaging.

Interventions

[18F] PBR111

Subjects will be injected with 5mCi (not to exceed a maximum of 5.5 mCi) of \[18F\]PBR111, followed by PET imaging.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. The participant is 50 years or older.

2. Written informed consent is obtained.

3. Participants have a clinical diagnosis of probable Alzheimer disease based on National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer Disease and Related Disorders Association (NINCDS/ADRDA) criteria.

4. Does not fulfill the ICC criteria for probable DLB (Appendix 3), the NINDS-AIREN for probable Vascular dementia (Appendix 5), or the Neary [Neary et al. 1998] criteria for FTD (Appendix 4)

5. Clinical Dementia Rating Scale score ≤ 2.

6. Modified Hachinski Ischemia Scale score of ≤ 4.

7. MRI brain scan findings that do not reveal changes indicative of stroke and/or generalized cerebrovascular disease (e.g., the ARWMC scale) changes limited to: a white matter lesion score of 0 or 1 or 2 and a basal ganglia score of 0 or 1)

8. has a caregiver willing and able to attend all study visits and perform the psychometric tests requiring the presence of a caregiver

9. For females, non-child bearing potential or a negative urine or blood pregnancy test on day of [18F]-PBR111 injection.

1. The participant is 18 years or older, with at least 4 subjects ≥50 years.

2. Written informed consent is obtained.

3. Negative history of neurological or psychiatric illness based on evaluation by a research physician.

4. Has no evidence of cognitive impairment as indicated by a clinical dementia rating (CDR, [Hughes et al. 1993]) score of 0 (zero) and a score of ≥ 28 in the Mini-Mental Status Examination (MMSE, [Folstein et al. 1975]) Clinical Dementia Rating score = 0.

5. has MRI brain scan that has been judged as "normal (age- appropriate)" including ARWMC scale [Wahlund et al. 2001] scores supporting the lack of cerebrovascular disease (e.g., a white matter lesion score of 0 or 1 or 2 and a basal ganglia score of 0 or 1) and a Scheltens scale [Scheltens et al. 1992] verifying the lack of cerebral atrophy (e.g. bilateral temporal lobe atrophy visual score of 0 or 1)

6. For females, non-child bearing potential a negative urine or blood pregnancy test on day of [18F]-PBR-111 injection.

Exclusion Criteria

1. History of significant cerebrovascular disease.

2. Clinically significant abnormal laboratory value and/or clinically significant unstable medical or psychiatric illness

3. Evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, neurological, immunodeficiency, pulmonary, or other disorder or disease.

4. Pregnancy

5. Contraindication to MRI examination, e.g. metal implants or phobia as determined by the onsite radiologist performing the scan

6. History of exposure to any radiation >15 mSv/year (e.g. occupational or radiation therapy)

7. Receiving drug therapy or other treatment that is known to lead to greatly fluctuating values of the hematological or chemical laboratory parameters or to severe side effects (e.g. chemotherapy)

8. Received anti-amyloid drug therapy.

1. History of significant cerebrovascular disease.

2. Clinically significant abnormal laboratory value and/or clinically significant unstable medical or psychiatric illness

3. Evidence of clinically significant gastrointestinal, cardiovascular, hepatic, renal, hematological, neoplastic, endocrine, neurological, immunodeficiency, pulmonary, or other disorder or disease.

4. Pregnancy

5. Contraindication to MRI examination, e.g. metal implants or phobia as determined by the on-site radiologist performing the scan

6. History of exposure to any radiation >15 mSv/year (e.g. occupational or radiation therapy)

7. Receiving drug therapy or other treatment that is known to lead to greatly fluctuating values of the hematological or chemical laboratory parameters or to severe side effects (e.g. chemotherapy)

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Institute for Neurodegenerative Disorders

OTHER

Sponsor Role: lead

Responsible Party

Danna Jennings, MD

Principal Investigator

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Danna Jennings, MD

Role: PRINCIPAL_INVESTIGATOR

Institute for Neurodegenerative Disorders

Locations

Institute for Neurodegenerative Disorders

New Haven, Connecticut, United States

Countries

United States

Other Identifiers

PBR111 001

Identifier Type: -

Identifier Source: org_study_id